Kong, Xiao-FeiWorley, LisaRinchai, DarawanBondet, VincentJithesh, Puthen VeettilGoulet, MarieNonnotte, EmilieRebillat, Anne SophieConte, MartineMircher, ClotildeGürtler, NicolasLiu, LuyanMigaud, MélanieElanbari, MohammedHabib, TanwirMa, Cindy SBustamante, JacintaAbel, LaurentRavel, AiméLyonnet, StanislasMunnich, ArnoldDuffy, DarraghChaussabel, DamienCasanova, Jean-LaurentTangye, Stuart GBoisson-Dupuis, StéphaniePuel, Anne
Summary
Down syndrome (DS) occurs when there are three copies of human chromosome 21 (HSA21), giving it the name trisomy 21. HSA21 contains a cluster of four receptor genes for interferons, proteins secreted in the body’s defense response. DS patients often develop infections and autoimmune diseases with symptoms that mimic other conditions with increased interferon signaling. The extra copies of genes found in trisomy 21 lead to what is called a “large gene dosage”. This analysis states that the heightened “gene dosage” at the site of these interferon receptor genes contributes to the mild type I interferonopathy experienced by those with Down Syndrome.
Abstract
Down syndrome (DS) is characterized by the occurrence of three copies of human chromosome 21 (HSA21). HSA21 contains a cluster of four interferon receptor (IFN-R) genes: IFNAR1, IFNAR2, IFNGR2, and IL10RB. DS patients often develop mucocutaneous infections and autoimmune diseases, mimicking patients with heterozygous gain-of-function (GOF) STAT1 mutations, which enhance cellular responses to three types of interferon (IFN). A gene dosage effect at these four loci may contribute to the infectious and autoimmune manifestations observed in individuals with DS. We report high levels of IFN-αR1, IFN-αR2, and IFN-γR2 expression on the surface of monocytes and EBV-transformed-B (EBV-B) cells from studying 45 DS patients. Total and phosphorylated STAT1 (STAT1 and pSTAT1) levels were constitutively high in unstimulated and IFN-α- and IFN-γ-stimulated monocytes from DS patients but lower than those in patients with GOF STAT1 mutations. Following stimulation with IFN-α or -γ, but not with IL-6 or IL-21, pSTAT1 and IFN-γ activation factor (GAF) DNA-binding activities were significantly higher in the EBV-B cells of DS patients than in controls. These responses resemble the dysregulated responses observed in patients with STAT1 GOF mutations. Concentrations of plasma type I IFNs were high in 12% of the DS patients tested (1.8% in the healthy controls). Levels of type I IFNs, IFN-Rs, and STAT1 were similar in DS patients with and without recurrent skin infections. We performed a genome-wide transcriptomic analysis based on principal component analysis and interferon modules on circulating monocytes. We found that DS monocytes had levels of both IFN-α- and IFN-γ-inducible ISGs intermediate to those of monocytes from healthy controls and from patients with GOF STAT1 mutations. Unlike patients with GOF STAT1 mutations, patients with DS had normal circulating Th17 counts and a high proportion of terminally differentiated CD8+ T cells with low levels of STAT1 expression. We conclude a mild interferonopathy in Down syndrome leads to an incomplete penetrance at both cellular and clinical level, which is not correlate with recurrent skin bacterial or fungal infections. The constitutive upregulation of type I and type II IFN-R, at least in monocytes of DS patients, may contribute to the autoimmune diseases observed in these individuals.
Conditions
Autoimmune Diseases, Disease Susceptibility, Genetic Predisposition to Disease, Infections, Mycoses